TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Island Pharmaceuticals Ltd ( (AU:ILA) ) has provided an announcement.
Island Pharmaceuticals Ltd has been granted a US patent for the use of Galidesivir in treating SARS-CoV-2, extending its patent protection until July 2042. This development strengthens Island’s intellectual property portfolio and supports Galidesivir’s potential as a broad-acting antiviral, aligning with the company’s strategy to advance its regulatory pathway for combating the Marburg virus.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on addressing urgent viral diseases, public health, or biosecurity threats. The company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir, targeting unmet medical needs in viruses such as Ebola, Marburg, MERS, Zika, and Yellow fever.
Average Trading Volume: 773,349
Technical Sentiment Signal: Buy
Current Market Cap: A$146.6M
See more data about ILA stock on TipRanks’ Stock Analysis page.